UPDATE: Brean Murray Carret Initiates Buy, $24 Target on Insulet

Brean Murray Carret initiates a Buy rating and $24 price target on Insulet PODD as the company presents an attractive growth story with a key approval looming in the near term. Brean Murray Carret notes, "We are initiating coverage of Insulet (PODD) with a Buy rating. Insulet is uniquely positioned in the $1B insulin pump market as the only supplier of a disposable patch insulin pump, the OmniPod, a highly differentiated product offering which has gained a strong following due to its ease of use and ease of training, among other features. A next gen version of the pump, EROS, finally appears close to FDA clearance, and further improves upon the existing technology  ‐ delivering a significant size reduction to wearers and a notable reduction in cost of goods." PODD closed at $19.11 per share on Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Price TargetInitiationIntraday UpdateMarketsAnalyst RatingsBrean Murray Carret
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!